Table 4.
Logistic regression models for pCR with p values, odds ratio, and confidence intervals
| miRNAs | Patients | All BC patients | HER2-positive patients | TNBC patients | |||
|---|---|---|---|---|---|---|---|
| Model | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |
| miR-20a | All | _ | _ | _ | _ | _ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb |
p = 0.020 1.39 (1.05–1.84) |
p = 0.019 1.41 (1.06–1.89) |
_ | _ | _ | _ | |
| miR-27b | All | _ | _ |
p = 0.035 1.30 (1.02–1.65) |
p = 0.050 1.28 (1.00–1.63) |
_ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb |
p = 0.038 1.27 (1.01–1.59) |
p = 0.030 1.30 (1.03–1.64) |
_ | _ | _ | _ | |
| miR-99b | All |
p = 0.103 1.14 (0.97–1.34) |
p = 0.039 1.19 (1.01–1.41) |
_ | _ | _ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| in PMCb | _ | _ | _ | _ | _ | _ | |
| miR-155 | All |
p = 0.002 1.25 (1.08–1.44) |
p = 0.003 1.24 (1.08–1.44) |
p = 0.049 1.24 (1.00–1.53) |
p = 0.035 1.26 (1.02–1.56) |
p = 0.013 1.29 (1.05–1.57) |
p = 0.018 1.29 (1.04–1.58) |
| In PM |
p = 0.033 1.26 (1.02–1.55) |
p = 0.049 1.24 (1.00–1.53) |
_ | _ | _ | _ | |
| In PMCb |
p = 0.032 1.24 (1.02–1.51) |
p = 0.023 1.27 (1.03–1.55) |
_ | _ | _ | _ | |
| miR-193b | All |
p = 0.039 1.13 (1.01–1.26) |
p = 0.055 1.12 (1.00–1.26) |
p = 0.010 1.26 (1.06–1.50) |
p = 0.012 1.26 (1.05–1.51) |
_ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb | _ | _ | _ | _ | _ | _ | |
| miR-301 | All |
p = 0.002 1.25 (1.08–1.44) |
p = 0.001 1.27 (1.10–1.46) |
p = 0.013 1.30 (1.06–1.60) |
p = 0.011 1.32 (1.07–1.64) |
_ | _ |
| In PM |
p = 0.040 1.22 (1.01–1.48) |
p = 0.028 1.25 (1.02–1.52) |
_ | _ | _ | _ | |
| In PMCb |
p = 0.020 1.28 (1.04–1.57) |
p = 0.022 1.29 (1.04–1.6) |
p = 0.012 1.53 (1.10–2.12) |
p = 0.016 1.51 (1.08–2..12) |
_ | _ | |
| miR-365 | All | _ | _ | _ | _ | _ | _ |
| In PM | _ | _ |
p = 0.052 1.35 (1.00–1.81) |
p = 0.038 1.39 (1.02–1.90) |
_ | _ | |
| In PMCb | _ | _ | _ | _ | _ | _ | |
| miR-423-5p | All |
p = 0.048 1.19 (1.00–1.42) |
p = 0.064 1.18 (0.99–1.41) |
_ | _ | _ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb | _ | _ | _ | _ | _ | _ | |
| miR-511 | All | _ | _ | _ | _ | _ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb | _ | _ | _ | _ |
p = 0.239 0.90 (0.76–1.07) |
p = 0.043 0.78 (0.62–0.99) |
|
| miR-628-5p | All | _ | _ | _ | _ |
p = 0.024 0.81 (0.67–0.97) |
p = 0.017 0.79 (0.65–0.96) |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb | _ | _ | _ | _ | _ | _ | |
| miR-660 | All | _ | _ |
p = 0.044 1.35 (1.01–1.80) |
p = 0.027 1.40 (1.04–1.89) |
_ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb | _ | _ | _ | _ | _ | _ | |
| miR-891a | All |
p = 0.063 1.07 (1.00–1.15) |
p = 0.036 1.08 (1.01–1.16) |
_ | _ | _ | _ |
| In PM | _ | _ | _ | _ | _ | _ | |
| In PMCb | _ | _ | _ | _ | _ | _ | |
Cells filled with “-” denote insignificant miRNA contributions to the models. MiRNAs which do not show significant contributions in any population were omitted. For each miRNA variable and each patient group, a univariate as well as a multivariate model with the covariables of age, nodal status, tumor size, and grading were calculated
The odds ratio with the 95% confidence interval and the associated Wald p value for the miRNAs are presented
PM non-carboplatin treatment arm, PMCb carboplatin treatment arm